Neurotransmitters such as dopamine, glutamate, and gamma-aminobutyric acid (GABA) play crucial roles in regulating cognitive functions including learning, memory, and executive control. Dysregulation in synthesis, release, and metabolism of these neurotransmitters is implicated in the pathogenesis of various neurological disorders, such as Alzheimer's disease, Parkinson's disease, depression, and schizophrenia, leading to significant cognitive impairment. Recent research highlights that dopamine modulates reward processing, motivation, and memory through its synthesis via tyrosine hydroxylase and reuptake via the dopamine transporter. Glutamate, the primary excitatory neurotransmitter, mediates synaptic plasticity and cognitive processes through ionotropic and metabotropic receptors, while gamma-aminobutyric acid maintains inhibitory balance via GABA A and GABA B receptors. Notedly, interactions among these neurotransmitters, such as dopamine-Glu cross-talk through N-methyl-D-aspartate and dopamine receptors, and GABAergic regulation of dopaminergic activity, are critical for cognitive function. Existing detection techniques, including microdialysis, electrochemical sensors, and genetically encoded indicators, have advanced our understanding but still lack the spatiotemporal resolution needed to fully capture dynamic neurotransmitter interactions in real time. Although pharmacological interventions targeting these systems (e.g., L-3,4-dihydroxyphenylalanine, ketamine, GABAergic modulators) show potential, clinical applications are limited by significant side effects and variable efficacy. In summary, a multi-target approach, combining advanced detection methods with a deeper understanding of neurotransmitter crosstalk, may pave the way for more effective diagnostic and treatment interventions for cognitive disorders.